CA-INVESTCLOUD
1.3.2023 14:18:01 CET | Business Wire | Press release
InvestCloud, the global leader in digital transformation for the financial industry with over $6 trillion in assets, today announced partnerships with leading asset managers, AssetCo and Westwood Group to innovate the digital distribution of financial products and strategies. Launching in the US initially, the partnership lays the foundation for both AssetCo and Westwood to tap into new markets through the InvestCloud platform’s global reach.
The partnership will see the investment strategies and financial products of AssetCo and Westwood distributed digitally via the InvestCloud Financial Supermarket (FSM)™ to financial advisors throughout the United States, starting this year. This includes the subsidiaries and associates of AssetCo—namely, River and Mercantile, SVM, Saracen, and Rize ETF.
Campbell Fleming, CEO of AssetCo, said: ”This is a time of dynamic change for AssetCo. Our partnership with InvestCloud plays a pivotal role in our transformational strategy in the US as we engage in a digital partnership to align ourselves with investors preferences of the future. We chose to partner with InvestCloud because of the quality of their digital capabilities and their global distribution. InvestCloud’s Financial Supermarket™ is a hugely innovative approach and very attractive for AssetCo and our operating companies as we support our growth strategy. InvestCloud’s digital approach to distribution will provide us with a highly efficient way for our products to reach a global audience. Through InvestCloud’s brilliant approach to data and their Digital Warehouse™, AssetCo will also attain key data insights on our strategies and our distribution across our markets, which will provide tremendous insights to serve our clients better.”
Brian Casey, CEO of Westwood Holdings Group, said: “Partnering with InvestCloud will transform the way we distribute financial products, opening up new channels and markets to reach more customers. This will help propel our growth, and in turn enable clients and advisors to more easily discover the products which best match their investment needs. We’re excited to be part of this digital revolution for financial products and portfolio construction.”
InvestCloud’s Financial Supermarket (FSM)™ will enable advisors to search for and select the best products for their clients, using industry-leading digital search capabilities and access to a multitude of virtual products, all in one digital location. The technology will also provide both AssetCo and Westwood with pace-setting data analytic capabilities to understand which products and content are resonating with specific segments.
AssetCo acquired River and Mercantile in June 2022. The partnership offers AssetCo an opportunity to quickly scale this business into the US marketplace.
Alex Hoctor-Duncan, CEO of River and Mercantile, said: “We are well aware of the potential opportunities in the US and believe our tailored strategies will be very successful through our partnership with InvestCloud. It’s an exciting new initiative, reinforcing our belief that as a dynamic boutique we can move with the times and change as the investment landscape changes. InvestCloud offers best-in-class digital distribution, with particularly powerful reach in the US, and we look forward to a very successful partnership.”
John Wise, CEO of InvestCloud, said: “We are excited to be partnering with two industry pioneers in Martin Gilbert and Brian Casey and their teams to transform the way financial products are distributed. InvestCloud has built the industry’s leading digital transformation platform with over $6 trillion in assets, and we continue to invest in innovation of the financial sector with our development of the Financial Supermarket™. These partnerships will offer tremendous distribution opportunities, with the potential to leverage over 400 wealth management firms with over 20 million investor accounts currently on InvestCloud’s global platform. We are confident that following our success together in the US, we will continue to drive growth by partnering with AssetCo in other key global markets.”
About InvestCloud
InvestCloud is a global company specializing in digital platforms that enable the development of financial solutions, pre-integrated into the cloud. The company offers on-demand client experiences and intuitive operations solutions using an ever-expanding suite of modular apps, resulting in powerful products including Communication (client portals, advisor portals, mobility and more), Planning (goal-based, cashflow, digital advice, proposals and more), Shopping & Selling (digital marketplace for financial products) and the App Library (IBOR, ABOR, performance and more). Headquartered in Los Angeles, InvestCloud has over 20 global offices including New York, London, Geneva, Singapore, Tokyo and Sydney, supporting trillions in assets across hundreds of diverse clients – from the largest banks in the world to wealth managers, asset managers and asset services companies.
InvestCloud’s clients today include over 150 asset managers, over 400 wealth managers and over 140,000 individual financial advisors. In North America alone, InvestCloud has eight of the top ten US banks and seven of the top ten US managed account sponsors.
For more information on InvestCloud, please visit www.investcloud.com
About AssetCo
AssetCo is a UK asset and wealth management business primarily involved in acquiring, managing and operating asset and wealth management activities and interests, together with other related services. The strategy principally focuses on making strategic acquisitions and building organic activities in areas of the asset and wealth management sector where structural shifts have the potential to deliver exceptional growth opportunities. This could include strategic acquisitions of undervalued asset and wealth management businesses which have core capabilities that play to these structural shifts and where active management can unlock value. Today, capabilities across the group include a listed equity businesses specialising in UK, European and Global assets, a private markets division focussed on UK Infrastructure, a sustainable thematic ETF business and a significant stake in a leading digital wealth management platform.
For more information on AssetCo, please visit www.assetco.com
About Westwood Holdings Group, Inc
Westwood Holdings Group, Inc. is a focused investment management boutique and wealth management firm. Westwood offers a broad array of investment solutions to institutional investors, private wealth clients and financial intermediaries. The firm specializes in distinct investment capabilities: U.S. Value Equity and Multi Asset, which includes Asset Allocation, Real Assets and Tactical, and are made available through separate accounts, the Westwood Funds® family of mutual funds and other pooled vehicles. Westwood benefits from significant, broad-based employee ownership and trades on the New York Stock Exchange under the symbol “WHG.” Based in Dallas, Westwood also maintains offices in Houston and San Francisco.
For more information on Westwood, please visit www.westwoodgroup.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230301005597/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 07:00:00 CEST | Press release
The ruling confirms that Beerenberg did not infringe Aspen Aerogels’ patents. The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. Th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom